Expertise in
2
conditions

Dr. Jennifer T. Eubanks

Hematology
Meridian Oncology Associates
1704 23rd Ave. 2nd Floor, 
Meridian, MS 
Accepting New Patients
Offers Telehealth
Referral may be required
Expertise in
2
conditions
Meridian Oncology Associates
1704 23rd Ave. 2nd Floor, 
Meridian, MS 

Overview

Jennifer Eubanks is a Hematologist practicing medicine in Meridian, Mississippi.

Dr. Eubanks is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses ALK-Positive Non-Small Cell Lung Cancer, Agranulocytosis, Thrombocytopenia, and Smoldering Multiple Myeloma.

She is actively involved in clinical research, participating in 10 clinical trials. Dr. Eubanks is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MS

Hospital Affiliations

Baptist-Anderson Regional Medical Center
Ochsner Rush Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Magnolia Health
  • HMO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Meridian Oncology Associates
1704 23rd Ave. 2nd Floor, Meridian, MS 39301

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological
Study Drugs: Nab-Paclitaxel, Cisplatin, Carboplatin, Cetuximab
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: April 21, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: 18F-Fluoromisonidazole, Carboplatin, Fludeoxyglucose F-18, Paclitaxel
Study Phase: Phase 2
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
View 9 Less Clinical Trials
Similar Doctors
Expertise in
13
conditions
Dr. John D. Voss
Hematology
Expertise in
13
conditions
Dr. John D. Voss
Hematology
Referral may be required
Before you request

Meridian Oncology Associates

1704 23rd Ave. 2nd Floor, 
Meridian, MS 
 (9.9 miles away)
601-482-1555
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Voss is a Hematologist practicing medicine in Meridian, Mississippi. Dr. Voss is highly rated in 13 conditions, according to our data. His clinical expertise encompasses ALK-Positive Non-Small Cell Lung Cancer, Gastric Lymphoma, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Gastrostomy. Dr. Voss is currently accepting new patients.

Expertise in
9
conditions
Dr. Sandeep Singh
Hematology | Oncology
Expertise in
9
conditions
Dr. Sandeep Singh
Hematology | Oncology
Referral may be required

South Central Regional Medical Center

1220 Jefferson St, 
Laurel, MS 
 (54.1 miles away)
601-426-4000
Experience:
18+ years
Languages Spoken:
English
See accepted insurances

Sandeep Singh is a Hematologist and an Oncologist practicing medicine in Laurel, Mississippi. He has been practicing medicine for over 18 years. Dr. Singh is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Breast Cancer, and Paget Disease of the Breast.

Expertise in
2
conditions
Expertise in
2
conditions
Referral may be required

Whitfield Regional Hospital

105 US Highway 80 E, 
Demopolis, AL 
 (51.1 miles away)
334-287-2647
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Alejandro Garcia-Hernandez is a Hematologist practicing medicine in Demopolis, Alabama. Dr. Garcia-Hernandez is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Anemia, Thrombocytopenia, Polycythemia Vera, and Vitamin B12 Deficiency. Dr. Garcia-Hernandez is currently accepting new patients.

Frequently Asked Questions about Dr. Jennifer T. Eubanks

How do I make an appointment with Dr. Jennifer T. Eubanks?

You can book an appointment with Dr. Jennifer T. Eubanks by calling their office at 601-482-1555. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jennifer T. Eubanks a top-rated expert for ALK-Positive Non-Small Cell Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jennifer T. Eubanks is classified as an Distinguished expert for ALK-Positive Non-Small Cell Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jennifer T. Eubanks specialize in?

While Dr. Jennifer T. Eubanks is a Hematology, they have specific expertise in ALK-Positive Non-Small Cell Lung Cancer, Agranulocytosis, and Thrombocytopenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jennifer T. Eubanks accept my insurance?

Dr. Jennifer T. Eubanks accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 601-482-1555 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Eubanks's expertise for a condition
ConditionClose
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile